Current status of radiotherapy with proton and light ion beams

Cancer

Volumn 109, Issue 7, 2007, Pages 1227-1238

  Greco, Carlo ^a,b   Wolden, Suzanne ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Intensity modulated radiotherapy; Light ions; Proton therapy; Radiotherapy; Second cancers

Indexed keywords

AWARENESS; BREAST CANCER; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; MATHEMATICAL MODEL; MORBIDITY; PHOTON; PRIORITY JOURNAL; PROSTATE CANCER; PROTON RADIATION; PROTON THERAPY; RADIOSENSITIVITY; RETINOBLASTOMA; REVIEW; SARCOMA; SECOND CANCER; THREE DIMENSIONAL IMAGING; TREATMENT INDICATION; UVEA MELANOMA;

HUMANS; IONS; NEOPLASMS; PHOTONS; PROTONS; RADIOTHERAPY, HIGH-ENERGY;

EID: 33947498611     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22542     Document Type: Review

References (101)

1. Brown A, Suit H. The centenary of the discovery of the Bragg peak. Radiother Oncol. 2004;73:265-268.
2. Lomax AJ, Bohringer T, Bolsi A, et al. Treatment planning and verification of proton therapy using spot scanning: initial experiences. Med Phys. 2004;31:3150-3157.
3. Lomax AJ, Pedroni E, Rutz H, et al. The clinical potential of intensity modulated proton therapy. Z Med Phys. 2004; 14:147-152.
4. Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836-849.
5. Jones B. The case for particle therapy. Br J Radiol. 2006;79; 24-31.
6. Paganetti H. Interpretation of proton relative biological effectiveness using lesion induction, lesion repair, and cellular dose distribution. Med Phys. 2005;32:2548-2556.
7. Kanai T, Matsufuji N, Miyamoto T, et al. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys. 2006;64:650-656.
8. Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol. 1997;28:348-354.
9. St. Clair W, Adams JA, Bues M, et al. Advantage of protons compared to conventional x-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys. 2004;58:727-734.
10. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys. 2005;63:362-372.
11. Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J. 2004;10:386-390.
12. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262-1267.
13. Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol. 1997; 15:1183-1189.
14. Imhof SM, Mounts MP, Hofman P, et al. Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology. 1996;103:263-268.
15. Krengli M, Hug EB, Adams JA, et al. Proton radiation therapy for retinoblastoma: comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys. 2005;61:583-593.
16. Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:1432-1438.
17. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys. 2005;63:1161-1168.
18. Delaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:492-498.
19. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97:769-777.
20. Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665-1671.
21. Gragoudas ES, Marie LA. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am. 2005;18:111-118, ix.
22. Gragoudas ES. A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma. Trans Am Ophthalmol Soc. 1998;96:691-720.
23. Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol. 1998; 125:81-89.
24. Char DH, Phillips T, Daftari I. Proton teletherapy of uveal melanoma. Int Ophthalmol Clin. 2006;46:41-49.
25. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55:867-880.
26. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology. 1999;106:1579-1587.
27. Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;91:432-439.
28. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999;175(Suppl 2):57-63.
29. Santoni R, Liebsch N, Finkelstein DM, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Radiat Oncol Biol Phys. 1998;41:59-68.
30. Hug EB, Sweeney RA, Nurre PM, et al. Proton radiotherapy in management of pediatric base of skull tumors. Int J Radiat Oncol Biol Phys. 2002;52:1017-1024.
31. Castro JR, Linstadt DE, Bahary JP, et al. Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J Radiat Oncol Biol Phys. 1994;29:647-655.
32. Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004;58:631-640.
33. Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol. 2003;179:598-605.
34. Hug EB, Fitzek MM, Liebsch NJ, et al. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys. 1995;31:467-476.
35. Weber DC, Trofimov AV, Delaney TF, et al. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys. 2004;58:1596-1606.
36. Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol. 2003;48:2617-2631.
37. Zimmermann FB, Bamberg M, Molls M, et al. Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol. 2003;21:91-97.
38. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48:107-114.
39. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946-1955.
40. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999;116:1313-1319.
41. Nihei K, Ogino T, Ishikura S, et al. High-dose proton beam therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:107-111.
42. Shioyama Y, Tokuuye K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:7-13.
43. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005;7:255-259.
44. Yamamoto N, Miyamoto T, Nishimura H, et al. Preoperative carbon ion radiotherapy for non-small cell lung cancer with chest wall invasion- pathological findings concerning tumor response and radiation induced lung injury in the resected organs. Lung Cancer. 2003;42:87-95.
45. Miyamoto T, Yamamoto N, Nishimura H, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003;66:127-140.
46. Koto M, Miyamoto T, Yamamoto N, et al. Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol. 2004;71:147-156.
47. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 2000;355:1757-1770.
48. Gyenes G, Rutqvist LE, Liedberg A, et al. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol. 1998;48:185-190.
49. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419-424.
50. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23:7475-7482.
51. Gagliardi G, Lax I, Soderstrom S, et al. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol. 1998;46:63-71.
52. Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24:4100-4106.
53. Minor GI, Yashar CM, Spanos WJ Jr, et al. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J. 2006;12:48-52.
54. Johansson J, Isacsson U, Lindman H, et al. Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. Radiother Oncol. 2002;65:89-98.
55. Lomax AJ, Cella L, Weber D, et al. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys. 2003;55:785-792.
56. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
57. Taghian AG, Kozak KR, Katz A, et al. Accelerated partial breast irradiation using proton beams: initial dosimetric experience. Int J Radiat Oncol Biol Phys. 2006;65:1404-1410.
58. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427-435.
59. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
60. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
61. Zietman AL, Desilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239.
62. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005;62:706-713.
63. Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005;62:3-19.
64. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415-1419.
65. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83-88.
66. Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62: 1195-11203.
67. Duttenhaver JR, Shipley WU, Perrone T, et al. Protons or megavoltage x-rays as boost therapy for patients irradiated for localized prostatic carcinoma. An early phase I/II comparison. Cancer. 1983;51:1599-1604.
68. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3-12.
69. Gardner BG, Zietman AL, Shipley WU, et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167: 123-126.
70. Slater JD, Rossi CJ Jr, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59:348-352.
71. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241-249.
72. Cella L, Lomax A, Miralbell R. New techniques in hadrontherapy: intensity modulated proton beams. Phys Med. 2001; 17(Suppl 1):100-102.
73. Griffin TW, Krall JM, Russell KJ, et al. Fast neutron irradiation of locally advanced prostate cancer. Semin Oncol. 1988;15:359-365.
74. Laramore GE, Krall JM, Thomas FJ, et al. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am J Clin Oncol. 1993;16:164-167.
75. Russell KJ, Caplan RJ, Laramore GE, et al. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Radiat Oncol Biol Phys. 1994; 28:47-54.
76. Linstadt DE, Castro JR, Phillips TL. Neon ion radiotherapy: results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 1991;20:761-769.
77. Akakura K, Tsujii H, Morita S, et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate. 2004; 58:252-258.
78. Tsuji H, Yanagi T, Ishikawa H, et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63:1153-1160.
79. Ishikawa H, Tsuji H, Kamada T, et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 2006;81:57-64.
80. Nikoghosyan A, Schulz-Ertner D, Didinger B, et al. Evaluation of therapeutic potential of heavy ion therapy for patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:89-97.
81. Engels H, Wambersie A. Relative biological effectiveness of neutrons for cancer induction and other late effects: a review of radiobiological data. Recent Results Cancer Res. 1998; 150:54-87.
82. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1-7.
83. Schneider U, Agosteo S, Pedroni E, et al. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys. 2002;53:244-251.
84. Gold DG, Neglia JP, Potish RA, et al. Second neoplasms following megavoltage radiation for pediatric tumors. Cancer. 2004;100:212-213.
85. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588-593.
86. Koshy M, Paulino AC, Mai WY, et al. Radiation-induced osteosarcomas in the pediatric population. Int J Radiat Oncol Biol Phys. 2005;63:1169-1174.
87. Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996;14:2818-2825.
88. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54: 824-829.
89. Movsas B, Hanlon AL, Pinover W, et al. Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys. 1998;41:251-255.
90. Chiouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2005;174:107-110.
91. Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398-406.
92. Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850-861.
93. Suit HD. Protons to replace photons in external beam radiation therapy? Clin Oncol (R Coll Radiol). 2003;15:S29-S31.
94. Goitein M, Jermann M. The relative costs of proton and x-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003;15: S37-S50.
95. Turesson I, Johansson KA, Mattsson S. The potential of proton and light ion beams in radiotherapy. Acta Oncol. 2003;42:107-114.
96. Dahl O. Protons. A step forward or perhaps only more expensive radiation therapy? Acta Oncol. 2005;44:798-800.
97. Munro AJ. Particle matters. Br J Radiol. 2006;79:276-277.
98. Lundkvist J, Ekman M, Ericsson SR, et al. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103:793-801.
99. Lundkvist J, Ekman M, Ericsson SR, et al. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75:179-185.
100. Bjork-Eriksson T, Glimelius B. The potential of proton beam radiation therapy in breast cancer. Acta Oncol. 2005;44:884-889.
101. Johansson B, Ridderheim M, Glimelius B. The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers. Acta Oncol. 2005;44:890-895.